Automate Your Wheel Strategy on QGEN
With Tiblio's Option Bot, you can configure your own wheel strategy including QGEN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol QGEN
- Rev/Share 9.5484
- Book/Share 16.8276
- PB 2.8376
- Debt/Equity 0.5829
- CurrentRatio 2.6001
- ROIC 0.0639
- MktCap 10353614260.0
- FreeCF/Share 2.2007
- PFCF 21.6937
- PE 25.5458
- Debt/Assets 0.3246
- DivYield 0.0316
- ROE 0.1148
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | QGEN | Barclays | -- | Overweight | -- | $55 | June 24, 2025 |
| Downgrade | QGEN | Redburn Atlantic | Buy | Neutral | -- | -- | April 4, 2025 |
| Downgrade | QGEN | Robert W. Baird | Outperform | Neutral | $52 | $42 | Feb. 19, 2025 |
| Downgrade | QGEN | Morgan Stanley | Overweight | Equal Weight | -- | $48 | Jan. 6, 2025 |
| Upgrade | QGEN | Jefferies | Hold | Buy | $42.5 | $54 | Dec. 10, 2024 |
| Downgrade | QGEN | HSBC Securities | Buy | Hold | -- | $49 | Oct. 17, 2024 |
News
Qiagen N.V. (QGEN) Deep Dive Into Sample Technologies: Leadership, Innovation and Future Expansion Transcript
Published: November 21, 2025 by: Seeking Alpha
Sentiment: Neutral
Qiagen N.V. ( QGEN ) Deep Dive Into Sample Technologies: Leadership, Innovation and Future Expansion November 21, 2025 9:00 AM EST Company Participants Domenica Martorana - Associate Director of Global Investor Relations Thierry Bernard - CEO, MD & Member of Management Board Daniel Wendorff John Gilardi - VP & Head of Corporate Communications Michael Scheffler Nitin Sood - Senior VP & Head of Product Portfolio & Innovation Fernando Beils Justus Krause-Harder Presentation Domenica Martorana Associate Director of Global Investor Relations Welcome to our next QIAGEN Deep Dive.
Read More
Qiagen N.V. (QGEN) Presents at Jefferies London Healthcare Conference 2025 Transcript
Published: November 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Qiagen N.V. ( QGEN ) Jefferies London Healthcare Conference 2025 November 19, 2025 5:30 AM EST Company Participants Roland Sackers - CFO, MD & Member of Management Board Daniel Wendorff John Gilardi - VP & Head of Corporate Communications Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division Welcome, everybody.
Read More
CellBxHealth rises on Qiagen tie-up to push Parsortix into more drug-development projects
Published: November 18, 2025 by: Proactive Investors
Sentiment: Positive
Shares in CelLBxHealth PLC (AIM:CLBX, NSX:ANPCY, OTCQB:ANPCF) climbed 7% to 1.93p after the company unveiled a collaboration with Qiagen designed to bring its Parsortix circulating tumour cell platform to a wider range of pharmaceutical partners. The agreement gives Qiagen the ability to bundle Parsortix into projects alongside its own molecular technologies, including polymerase chain reaction, digital polymerase chain reaction and next-generation sequencing.
Read More
CellBxHealth strikes co-marketing deal with Qiagen to widen use of Parsortix cancer platform
Published: November 18, 2025 by: Proactive Investors
Sentiment: Positive
CelLBxHealth PLC (AIM:CLBX, NSX:ANPCY, OTCQB:ANPCF) has agreed a collaboration and co-marketing deal with Qiagen that will allow the diagnostics group to promote the UK company's Parsortix system to drugmakers, opening the door to new projects in circulating tumour cell research and early diagnostic development. The non-exclusive agreement enables Qiagen to offer the Parsortix platform to its pharmaceutical partners as part of projects that combine circulating tumour cell enrichment with Qiagen's polymerase chain reaction, digital polymerase chain reaction and next-generation sequencing technologies.
Read More
Qiagen N.V. (QGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Neutral
Qiagen N.V. ( QGEN ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 12:40 PM EST Company Participants Thierry Bernard - CEO, MD & Member of Management Board Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Presentation Douglas Schenkel Wolfe Research, LLC All right.
Read More
Qiagen (QGEN) International Revenue in Focus: Trends and Expectations
Published: November 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Read More
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Seattle's Parse Biosciences to be acquired by Qiagen for $225M
Published: November 06, 2025 by: GeekWire
Sentiment: Positive
Seattle's Parse Biosciences is teed up for an acquisition by Qiagen, a Netherlands-based holding company, in a $225 million cash
Read More
Qiagen N.V. (QGEN) Q3 2025 Earnings Call Transcript
Published: November 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Qiagen N.V. ( QGEN ) Q3 2025 Earnings Call November 5, 2025 9:30 AM EST Company Participants John Gilardi - VP & Head of Corporate Communications Thierry Bernard - CEO, MD & Member of Management Board Roland Sackers - CFO, MD & Member of Management Board Conference Call Participants Jack Meehan - Nephron Research LLC Hugo Solvet - BNP Paribas, Research Division Douglas Schenkel - Wolfe Research, LLC Casey Woodring - JPMorgan Chase & Co, Research Division Aisyah Noor - Morgan Stanley, Research Division Patrick Donnelly - Citigroup Inc., Research Division Luke Sergott - Barclays Bank PLC, Research Division Jan …
Read More
QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase
Published: November 04, 2025 by: Business Wire
Sentiment: Neutral
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the third quarter of 2025 and reaffirmed its outlook for solid profitable growth while raising its profitability targets. QIAGEN reaffirmed its FY 2025 outlook for net sales growth of about 4-5% CER (about 5-6% CER core sales excluding divestments) and raised its adjusted diluted EPS target to about $2.38 CER (previously about $2.35 CER). QIAGEN also expects an adjusted opera.
Read More
QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions
Published: November 04, 2025 by: Business Wire
Sentiment: Neutral
VENLO, Netherlands & SEATTLE--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research. The acquisition will significantly expand QIAGEN's Sample technologies portfolio into the fast-growing single-cell sequencing market with highly scalable chemistry designed to power research involving up to millions and bi.
Read More
Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Negative
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
QGEN vs. ACAD: Which Stock Is the Better Value Option?
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Qiagen (QGEN) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value investors?
Read More
Qiagen N.V. (QGEN) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Published: September 25, 2025 by: Seeking Alpha
Sentiment: Neutral
Qiagen N.V. (NYSE:QGEN ) Bank of America Global Healthcare Conference 2025 September 25, 2025 5:45 AM EDT Company Participants John Gilardi - VP & Head of Corporate Communications Conference Call Participants Michael Ryskin - BofA Securities, Research Division Presentation Michael Ryskin BofA Securities, Research Division Thanks for joining us.
Read More
QGEN Stock Gains From CE-IVDR Certification for QIAstat-Dx Portfolio
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive
QIAGEN secures CE-IVDR certification for its full QIAstat-Dx portfolio, boosting its diagnostics arm and lifting shares.
Read More
QIAGEN Stock May Benefit From the US Clearance of QIAstat-Dx Rise
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
QGEN announces the launch of FDA-cleared QIAstat-Dx Rise, which may boost U.S. diagnostic access and testing capacity worldwide.
Read More
QIAGEN N.V. Announces Successful Placement of New Net Share Settled Convertible Bonds
Published: August 28, 2025 by: Business Wire
Sentiment: Neutral
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN") announces certain terms of the new senior, unsecured net share settle.
Read More
Qiagen: Diagnostics Vs. Life Sciences Pair Trade Analysis
Published: August 21, 2025 by: Seeking Alpha
Sentiment: Positive
Diagnostics now outperform Life Sciences due to academic funding cuts, making Qiagen's defensive profile more attractive in the current market. Qiagen offers stable growth, high profitability, and low leverage, providing a resilient investment option amid sector volatility and macroeconomic uncertainty. While Qiagen is a strong short-term buy, investors should also consider peers like SysMex, BioMerieux, and CellaVision for diversification and growth potential.
Read More
Why Qiagen (QGEN) International Revenue Trends Deserve Your Attention
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
Examine the evolution of Qiagen's (QGEN) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Read More
Qiagen N.V. (QGEN) Q2 2025 Earnings Call Transcript
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Qiagen N.V. (NYSE:QGEN ) Q2 2025 Earnings Conference Call August 6, 2025 9:30 AM ET Company Participants John Gilardi - Vice President of Corporate Communications & Investor Relations Roland Sackers - CFO, MD & Member of Management Board Thierry Bernard - CEO, MD & Member of Management Board Conference Call Participants Aisyah Noor - Morgan Stanley, Research Division Casey Rene Woodring - JPMorgan Chase & Co, Research Division Daniel Gregory Brennan - TD Cowen, Research Division Daniel Louis Leonard - UBS Investment Bank, Research Division Douglas Anthony Schenkel - Wolfe Research, LLC Harry MacKinnon Gillis - Joh.
Read More
Why Qiagen (QGEN) is a Top Growth Stock for the Long-Term
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
QGEN or EXAS: Which Is the Better Value Stock Right Now?
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Qiagen (QGEN) or Exact Sciences (EXAS). But which of these two stocks presents investors with the better value opportunity right now?
Read More
QGEN vs. EXAS: Which Stock Is the Better Value Option?
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Qiagen (QGEN) and Exact Sciences (EXAS). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Here's Why Qiagen (QGEN) is a Strong Value Stock
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Qiagen (QGEN) Just Flashed Golden Cross Signal: Do You Buy?
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
From a technical perspective, QIAGEN N.V. (QGEN) is looking like an interesting pick, as it just reached a key level of support.
Read More
Here's Why Qiagen (QGEN) is a Strong Growth Stock
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
QIAGEN's New QIAcuity dPCR IVD Pact With GENCURIX May Boost Its Stock
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Positive
QGEN teams with GENCURIX to expand its digital PCR IVD offerings, aiming to strengthen its precision diagnostics arm.
Read More
QGEN Stock Rises in After Market Following Partnership With Incyte
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
QIAGEN teams up with Incyte to develop NGS-based companion diagnostics for blood cancers.
Read More
Should You Add QIAGEN Stock to Your Portfolio for Now?
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Negative
QGEN rides on test menu growth, strategic partnerships, and strong solvency, despite macro and market headwinds.
Read More
Here's Why Qiagen (QGEN) is a Strong Momentum Stock
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
About Qiagen N.V. (QGEN)
- IPO Date 1996-06-28
- Website https://www.qiagen.com
- Industry Medical - Diagnostics & Research
- CEO Thierry Bernard
- Employees 5700